Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRJF2Q)

Drug Name

Citatuzumab bogatox Drug Info

Synonyms

VB6-845; Antibody therapeutic (ovary tumor), Viventia; Ovary cancer therapeutic (antibody), Viventia; Anti-EpCAM-bouganin conjugate (anticancer), Viventia

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

TTD Drug ID: DMRJF2Q

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tumor-associated calcium signal transducer 1 (EPCAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vicineum	DMLO0KD	Bladder cancer	2C94	Phase 3	[3]
VB4-845	DMGKRAJ	Head and neck cancer	2D42	Phase 2/3	[4]
CAR-T Cells targeting EpCAM	DMREQCF	Colon cancer	2B90.Z	Phase 1/2	[5]
CAR-T Cells targeting EpCAM	DMREQCF	Colon cancer	2B90.Z	Phase 1/2	[6]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
A-337	DMRWTFG	Non-small-cell lung cancer	2C25.Y	Phase 1	[8]
CAR-T cells recognizing EpCAM	DMC7Y5F	Breast cancer	2C60-2C65	Phase 1	[9]
ING-1	DM5WCBM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
EPCAM-targeted CAR-T cells	DMV6RMB	Gastric adenocarcinoma	2B72	Clinical trial	[11]
IGN-101	DMOG1LX	Colorectal cancer	2B91.Z	Discontinued in Phase 2	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor-associated calcium signal transducer 1 (EPCAM)	TTZ8WH4	EPCAM_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00481936) Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin. U.S. National Institutes of Health.
2	Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother Radiopharm. 2012 Nov;27(9):582-92.
3	Clinical pipeline report, company report or official report of Sesen Bio.
4	A bispecific EpCAM/CD133 targeted toxin is effective against carcinoma. Target Oncol. 2014 September; 9(3): 239-249.
5	ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
6	ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
7	EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
8	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
9	ClinicalTrials.gov (NCT02915445) EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer
10	ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res. 2004 Nov 15;10(22):7555-65.
11	ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer
12	Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer. Curr Opin Mol Ther. 2006 Aug;8(4):358-65.